These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 9472630)

  • 1. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
    Holford J; Sharp SY; Murrer BA; Abrams M; Kelland LR
    Br J Cancer; 1998; 77(3):366-73. PubMed ID: 9472630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473).
    Holford J; Raynaud F; Murrer BA; Grimaldi K; Hartley JA; Abrams M; Kelland LR
    Anticancer Drug Des; 1998 Jan; 13(1):1-18. PubMed ID: 9474239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF; Hunakova L; Kelland LR
    Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines.
    Holford J; Beale PJ; Boxall FE; Sharp SY; Kelland LR
    Eur J Cancer; 2000 Oct; 36(15):1984-90. PubMed ID: 11000581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
    Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ; Kelland LR
    Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ; Kelland LR; Harrap KR
    Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
    McKeage MJ; Abel G; Kelland LR; Harrap KR
    Br J Cancer; 1994 Jan; 69(1):1-7. PubMed ID: 8286188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.
    Loh SY; Mistry P; Kelland LR; Abel G; Harrap KR
    Br J Cancer; 1992 Dec; 66(6):1109-15. PubMed ID: 1457352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
    Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
    J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)].
    Mellish KJ; Barnard CF; Kelland LR; Harrap KR
    Int J Cancer; 1994 Oct; 59(1):65-70. PubMed ID: 7927906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
    Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
    J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines.
    Pestell KE; Medlow CJ; Titley JC; Kelland LR; Walton MI
    Int J Cancer; 1998 Sep; 77(6):913-8. PubMed ID: 9714063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
    Orr RM; O'Neill CF; Nicolson MC; Barnard CF; Murrer BA; Giandomenico CM; Vollano JF; Harrap KR
    Br J Cancer; 1994 Sep; 70(3):415-20. PubMed ID: 8080724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.
    Sharp SY; Smith V; Hobbs S; Kelland LR
    Br J Cancer; 1998 Jul; 78(2):175-80. PubMed ID: 9683290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
    Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
    Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.